Biosimilars for the management of rheumatoid arthritis: Economic considerations

Expert Review of Clinical Immunology

Volumn 11, Issue , 2015, Pages S43-S52

  Gulácsi, László ^a   Brodszky, Valentin ^a   Baji, Petra ^a   Kim, HoUng ^b   Kim, Su Yeon ^b   Cho, Yu Young ^b   Péntek, Márta ^a  

^a Institute of Data Analytics and Information Systems   (Hungary)

^b Celltrion Inc   (South Korea)

Author keywords

biosimilar; budget savings; cost effectiveness; CT P13; pharmacoeconomics; rheumatoid arthritis

Indexed keywords

BIOSIMILAR AGENT; CT P 13; INFLIXIMAB; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; CT-P13; MONOCLONAL ANTIBODY;

COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ECONOMIC ASPECT; HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; ARTHRITIS, RHEUMATOID; COST BENEFIT ANALYSIS; ECONOMICS; OUTCOME ASSESSMENT; PROCEDURES; STATISTICAL MODEL;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOSIMILAR PHARMACEUTICALS; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; INFLIXIMAB; MODELS, ECONOMIC; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84942256493     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2015.1090313     Document Type: Review

References (69)

1. Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 2014;73: 1316-22
2. Ollier WE, Harrison B, Symmons D. What is the natural history of rheumatoid arthritis? Best Pract Res Clin Rheumatol 2001;15:27-48
3. McInnes IB, O'Dell JR. State-of-the-art: rheumatoid arthritis. Ann Rheum Dis 2010;69:1898-906
4. Furneri G, Mantovani LG, Belisari A, et al. Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. Clin Exp Rheumatol 2012;30:S72-84
5. Gabriel SE. Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med 2008;121:S9-14
6. Lundkvist J, Kastang F, Kobelt G. The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ 2008;8(Suppl 2):S49-60
7. Orlewska E, Ancuta I, Anic B, et al. Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries. Med Sci Monit 2011;17: SR1-13
8. World Health Organization. Expert Committee on Biological Standardization. Geneva, 19 to 23 October 2009. Guidelines on evaluation of similar biotherapeutic products (SBPs). Available from: www.who. int/biologicals/areas/biological-therapeutics/BIOTHERAPEUTICS-FOR-WEB-22APRIL2010.pdf [Last accessed 28 July 2015]
9. Pentek M, Kobelt G, Czirjak L, et al. Costs of rheumatoid arthritis in Hungary. J Rheumatol 2007;34:1437
10. Pentek M, Szekanecz Z, Czirjak L, et al. Impact of disease progression on health status, quality of life and costs in rheumatoid arthritis in Hungary. Orv Hetil 2008;149:733-41
11. Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol 2005;23:S14-18
12. Ma VY, Chan L, Carruthers KJ. Incidence, prevalence, costs, and impact on disability of common conditions requiring rehabilitation in the United States: stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, osteoarthritis, rheumatoid arthritis, limb loss, and back pain. Arch Phys Med Rehabil 2014;95:986-95
13. Sullivan PW, Ghushchyan V, Huang XY, et al. Influence of rheumatoid arthritis on employment, function, and productivity in a nationally representative sample in the United States. J Rheumatol 2010;37:544-9
14. Burton W, Morrison A, Maclean R, et al. Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med (Lond) 2006;56:18-27
15. Eberhardt K, Larsson BM, Nived K, et al. Work disability in rheumatoid arthritis-development over 15 years and evaluation of predictive factors over time. J Rheumatol 2007;34:481-7
16. Birnbaum H, Pike C, Kaufman R, et al. Societal cost of rheumatoid arthritis patients in the US. Curr Med Res Opin 2010;26: 77-90
17. Maetzel A, Li LC, Pencharz J, et al. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis 2004;63:395-401
18. Benucci M, Saviola G, Manfredi M, et al. Cost effectiveness analysis of disease-modifying antirheumatic drugs in rheumatoid arthritis. A systematic review literature. Int J Rheumatol 2011;2011:845496
19. Horvath CZ, Sebestyen A, Osterle A, et al. Economic burden of long-term care of rheumatoid arthritis patients in Hungary. Eur J Health Econ 2014;15(Suppl 1): S131-5
20. Krol M, Papenburg J, van Exel J. Does including informal care in economic evaluations matter? A systematic review of inclusion and impact of informal care in cost-effectiveness studies. Pharmacoeconomics 2015;33:123-35
21. Kawatkar AA, Jacobsen SJ, Levy GD, et al. Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the medical expenditure panel survey. Arthritis Care Res (Hoboken) 2012;64:1649-56
22. Nam JL, Ramiro S, Gaujoux-Viala C, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2014;73:516-28
23. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50: 3432-43
24. Kuek A, Hazleman BL, Ostor AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J 2007;83:251-60
25. Fischer MA, Polinski JM, Servi AD, et al. Prior authorization for biologic disease-modifying antirheumatic drugs: a description of US Medicaid programs. Arthritis Rheum 2008;59:1611-17
26. Modena V, Bianchi G, Roccatello D. Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target? Autoimmun Rev 2013;12:835-8
27. Nurmohamed MT, Dijkmans BA. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs 2005;65:661-94
28. Dorner T, Strand V, Castaneda-Hernandez G, et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 2013;72:322-8
29. Yoo DH. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis. Expert Rev Clin Immunol 2014;10:981-3
30. van der Velde G, Pham B, Machado M, et al. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken) 2011;63:65-78
31. Gulacsi L, Rencz F, Pentek M, et al. Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries. Eur J Health Econ 2014;15(Suppl 1):S27-34
32. Joensuu JT, Huoponen S, Aaltonen KJ, et al. The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review. PLoS ONE 2015;10: e0119683
33. Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis 2014;73:198-206
34. Rencz F, Pentek M, Bortlik M, et al. Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe. World J Gastroenterol 2015;21: 1728-37
35. Rencz F, Kemeny L, Gajdacsi J, et al. Use of biologics for psoriasis in Central and Eastern European countries. J Eur Acad Dermatol Venereol 2015; In Press
36. Pease C, Pope JE, Truong D, et al. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy. Semin Arthritis Rheum 2011;41: 81-9
37. Sokka T, Kautiainen H, Pincus T, et al. Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann Rheum Dis 2009;68:1666-72
38. Desai RJ, Rao JK, Hansen RA, et al. Predictors of treatment initiation with tumor necrosis factor-alpha inhibitors in patients with rheumatoid arthritis. J Manag Care Pharm 2014;20:1110-20
39. Haustein R, de Millas C, Hoer A, et al. Saving money in the European healthcare systems with biosimilars. Generics and Biosimilars Initiative Journal 2012;1:120-6
40. Gascon P, Tesch H, Verpoort K, et al. Clinical experience with Zarzio(R) in Europe: what have we learned? Support Care Cancer 2013;21:2925-32
41. Verpoort K, Mohler TM. A non-interventional study of biosimilar granulocyte colony-stimulating factor as prophylaxis for chemotherapy-induced neutropenia in a community oncology centre. Ther Adv Med Oncol 2012;4: 289-93
42. Lapadula G, Ferraccioli GF. Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues. Clin Exp Rheumatol 2012;30:S102-6
43. Abraham I, Han L, Sun D, et al. Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries. Future Oncol 2014;10:1599-609
44. Horbrand F, Rottenkolber D, Fischaleck J, et al. Erythropoietin-induced treatment costs in patients suffering from renal anemia - a comparison between biosimilar and originator drugs. Gesundheitswesen 2014;76:e79-84
45. Wu B, Song Y, Leng L, et al. Treatment of moderate rheumatoid arthritis with different strategies in a health resource-limited setting: a cost-effectiveness analysis in the era of biosimilars. Clin Exp Rheumatol 2015;33:20-6
46. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013;72:1613-20
47. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013;72:1605-12
48. Baji P, Pentek M, Szanto S, et al. Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis. Eur J Health Econ 2014; 15(Suppl 1):S45-52
49. Baji P, Pentek M, Czirjak L, et al. Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. Eur J Health Econ 2014;15(Suppl 1):S53-64
50. NICE. Draft guidance for consultation: Ankylosing spondylitis and axial spondyloarthritis (non-radiographic) - adalimumab, etanercept infliximab and golimumab (inc rev TA143 and TA233) ID694. Available from: www.nice.org.uk/guidance/indevelopment/gid-tag355 2015. [Last accessed 24 June 2015]
51. Kim J, Hong J, Kudrin A. 5 year budget impact analysis of biosimilar infliximab for the treatment of rheumatoid arthritis in UK, Italy, France and Germany. Arthritis Rheumatol 2014;11(Suppl):S512 (abstract 1166)
52. Brodszky V, Baji P, Balogh O, Pentek M. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur J Health Econ 2014;15(Suppl 1):S65-71
53. McCarthy G, Ebel BC, Guy H. Introduction of an infliximab biosimilar (CT-P13): A five-year budget impact analysis for the treatment of rheumatoid arthritis in Ireland. Value Health 2013;16: A558 (PMS22)
54. Lucioni C, Mazzi S, Caporali R. Budget impact analysis of infliximab biosimilar: the Italian scenery. Global & Regional Health Technology Assessment 2015:Advanced online publication
55. Kim J, An Hong J, Kudrin A. 5 year budget impact analysis of CT-P13 (infliximab) for the treatment of Crohn's disease in UK, Italy and France. J Crohns Colitis 2015;9(Suppl 1):S144 (P137)
56. Jha A, Dunlop W, Upton A. Budget impact analysis of introducing biosimilar infliximab for the treatment of gastro intestinal disorders in five European countries. J Crohns Colitis 2015;9(Suppl 1):S427 (P691)
57. Brodszky N, Rencz F, Pentek M, et al. A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania and Slovakia. Expert Rev Pharmacoecon Outcomes Res 2015. [Epub ahead of print]
58. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63
59. Gulacsi L. Biological and biosimilar therapies in inflammatory conditions: challenges for the Central and Eastern European countries. Eur J Health Econ 2014;15(Suppl 1):S1-4
60. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509
61. Grabowski H, Guha R, Salgado M. Biosimilar competition: lessons from Europe. Nat Rev Drug Discov 2014;13: 99-100
62. Grabowski D, Henderson B, Lam D, et al. Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists. Clin Rheumatol 2015. [Epub ahead of print]
63. Danese S, Fiorino G, Michetti P. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization. J Crohns Colitis 2014;8:1548-50
64. Park W, Jaworski J, Brzezicki J, et al. A randomised, double-blind, parallel-group, phase 1 study comparing the pharmacokinetics, safety and efficacy of CT-P13 and infliximab in patients with active ankylosing spondylitis: 54 week results from the PLANETAS study. Ann Rheum Dis 2013;72(Suppl 3):516 [FRI0421]
65. Yoo DH, Racewicz A, Brzezicki J, et al. A phase 3 randomised controlled trial to compare CT-P13 with infliximab in patients with active rheumatoid arthritis: 54 week results from the PLANETRA study. Ann Rheum Dis 2013; 72(Suppl 3):73 [OP0068]
66. Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with rheumatoid arthritis: comparison between continued CT-P13 and switching from infliximab to CT-P13. Arthritis Rheum 2013;65:3319 (L1)
67. Park W, Miranda P, Brzosko M, et al. Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with ankylosing spondylitis: comparison between continuing with CT-P13 and switching from infliximab to CT-P13. Arthritis Rheum 2013;65:3326 (L15)
68. Baji P, Gulacsi L, Lovasz D, et al. Treatment preferences of originator versus biosimilar drugs in Crohn's disease; discrete choice experiment among gastroenterologists. Scand J Gastroenterol 2015. [Epub ahead of print]
69. Brodszky V, Bálint P, Géher P, et al. Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. Rheumatol Int 2009;30:199-205